Loading patent…
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsRobert Babb, Gang Chen, Christopher Daly, John DaSilva, Douglas MacDonald, Thomas Nittoli
Estimating the term…
Provided herein are antibodies and bispecific antigen-binding molecules that bind MET and methods of use thereof. The bispecific antigen-binding molecules comprise a first and a second antigen-binding domain, wherein the first and second antigen-binding domains bind to two different (preferably non-overlapping) epitopes of the extracellular domain of human MET. The bispecific antigen-binding molecules are capable of blocking the interaction between human MET and its ligand HGF. The bispecific antigen-binding molecules can exhibit minimal or no MET agonist activity, e.g., as compared to monovalent antigen-binding molecules that comprise only one of the antigen-binding domains of the bispecific molecule, which tend to exert unwanted MET agonist activity. Also included are antibody-drug conjugates (ADCs) comprising the antibodies or bispecific antigen-binding molecules provided herein linked to a cytotoxic agent, radionuclide, or other moiety, as well as methods of treating cancer in a subject by administering to the subject a bispecific antigen-binding molecule or an ADC thereof.
A bispecific antigen-binding molecule comprising:
A bispecific antigen-binding molecule comprising:
A method for preparing an antibody-drug conjugate comprising contacting:
An antibody-drug conjugate prepared by the process of:
A bispecific antigen-binding molecule comprising:
A bispecific antigen-binding molecule comprising:
Dependencies are inferred from the claim text.